| # | Title | Journal | Year | Citations |
|---|
| 1 | iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL | Blood | 2018 | 1,069 |
| 2 | Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) | Blood | 2012 | 520 |
| 3 | Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2015 | 458 |
| 4 | Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia | Journal of Clinical Oncology | 2010 | 437 |
| 5 | Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome | Leukemia | 2019 | 396 |
| 6 | 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party | Blood | 2021 | 305 |
| 7 | Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2021 | 265 |
| 8 | First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial | Blood | 2008 | 247 |
| 9 | Drug resistance in multiple myeloma | Cancer Treatment Reviews | 2018 | 200 |
| 10 | Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia | Blood | 2017 | 193 |
| 11 | Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial | Lancet, The | 2020 | 188 |
| 12 | Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial | Blood | 2000 | 165 |
| 13 | Skin lesions in chronic lymphocytic leukemia | Leukemia and Lymphoma | 2007 | 152 |
| 14 | Current and emerging therapies for acute myeloid leukemia | Clinical Therapeutics | 2009 | 129 |
| 15 | Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2) | Blood | 2006 | 119 |
| 16 | Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL | Blood | 2017 | 111 |
| 17 | Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results | American Journal of Hematology | 2018 | 98 |
| 18 | Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later | Drugs in R and D | 2019 | 98 |
| 19 | New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies | BioDrugs | 2011 | 96 |
| 20 | Hairy-cell leukemia variant: Recent view on diagnosis, biology and treatment | Cancer Treatment Reviews | 2011 | 95 |
| 21 | Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study | Lancet Oncology, The | 2018 | 93 |
| 22 | Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21 | Oncotarget | 2016 | 88 |
| 23 | Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway | Anti-Cancer Drugs | 2006 | 87 |
| 24 | Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study) | Journal of Clinical Oncology | 2010 | 86 |
| 25 | High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies | Blood | 2018 | 83 |
| 26 | Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia | Leukemia | 2002 | 81 |
| 27 | Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2015 | 81 |
| 28 | The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy | Cellular and Molecular Biology Letters | 2005 | 80 |
| 29 | Safety and Tolerability of Antibody-Drug Conjugates in Cancer | Drug Safety | 2019 | 75 |
| 30 | 2‐Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7‐year experience in Poland | European Journal of Haematology | 1999 | 73 |
| 31 | Exposure of cells to static magnetic field accelerates loss of integrity of plasma membrane during apoptosis | Cytometry | 2002 | 72 |
| 32 | Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders | Expert Opinion on Investigational Drugs | 2012 | 72 |
| 33 | Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial | Blood | 2007 | 70 |
| 34 | Purine Nucleoside Analogues in the Treatment of Myleoid Leukemias | Leukemia and Lymphoma | 2003 | 69 |
| 35 | Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study | Leukemia | 2021 | 63 |
| 36 | Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia | Blood Advances | 2020 | 60 |
| 37 | Plasmablastic Transformation of Low-grade B-cell Lymphomas | American Journal of Surgical Pathology | 2013 | 59 |
| 38 | Toll-like receptors and their role in carcinogenesis and anti-tumor treatment | Cellular and Molecular Biology Letters | 2009 | 58 |
| 39 | The inhibitor of apoptosis protein family and its antagonists in acute leukemias | Apoptosis: an International Journal on Programmed Cell Death | 2004 | 56 |
| 40 | Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus | Mediators of Inflammation | 2014 | 56 |
| 41 | Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia | Blood | 2012 | 55 |
| 42 | Combination Regimen of Cladribine (2-Chlorodeoxyadenosine), Cytarabine and G-CSF (CLAG) as Induction Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia | Leukemia and Lymphoma | 2000 | 54 |
| 43 | Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment | Clinical Lymphoma and Myeloma | 2008 | 54 |
| 44 | The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis | European Cytokine Network | 1998 | 53 |
| 45 | Monoclonal Antibodies in the Treatment of Chronic Lymphoid Leukemias | Leukemia and Lymphoma | 2004 | 52 |
| 46 | Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma | Cancer | 2006 | 50 |
| 47 | Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911) | Blood | 2013 | 49 |
| 48 | Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy | Leukemia and Lymphoma | 2015 | 48 |
| 49 | Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations | Leukemia | 2021 | 48 |
| 50 | Circulating endothelial cells in patients with acute myeloid leukemia | European Journal of Haematology | 2005 | 47 |
